First Tracks Biotherapeutics

ANB101 targets BDCA2 on plasmacytoid dendritic cells to inhibit interferon secretion and reduce immune activation in autoimmune and inflammatory diseases.

Advancing a broad portfolio with purpose and precision With deep research expertise and a pioneering mindset, we advance a broad portfolio, generate rigorous translational and clinical data, and innovate in clinical development to accelerate proof‑of‑concept and global registration. Our pipeline Our programs ANB033 ANB033 is a novel anti‑CD122 antagonist that targets the shared beta subunit

We engineer our antibodies for top down impact By targeting activated immune cells in both the periphery and affected tissues, we modulate the critical pathways that regulate autoimmunity and inflammation.Dysregulated immune responses fuel a wide range of autoimmune and inflammatory diseases across gastroenterology, rheumatology, dermatology and respiratory therapeutic areas. These large, underserved patient populations often

Beth led human resources at Dendreon and Avanir and held increasing roles at Allergan, Takeda, and TAP Pharmaceuticals. She earned a BBA in Human Resources from the University of Iowa and a Master’s in Organizational Development from the University of Arizona.

Carlos Garcia joined First Tracks Biotherapeutics in August 2026 as Senior Vice President, CMC.

Monique led Global Communications at AVROBIO and previously served as Vice President of Corporate Communications at Spark Therapeutics, where she managed communications for the first U.S. gene therapy approval for a genetic disease.

Nicole has nearly 20 years of legal experience in biopharmaceutical, medical technology, and data and technology companies. She previously served as vice president and assistant general counsel at Bristol Myers Squibb, leading legal work for RayzeBio, BMS’s radiopharmaceutical subsidiary.

First Tracks Biotherapeutics provides contact information for general inquiries, investor relations, media, sponsorships, scientific and medical information, and clinical trial inquiries.

A clinical-stage biotechnology company focused on addressing unmet medical needs in autoimmune and inflammatory diseases.